GERMANTOWN, Md., Sept. 10, 2020 /PRNewswire/ -- Seneca
Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused
on developing novel treatments for diseases of high unmet medical
need, today announced that the last subject completed their final
follow-up assessment in the Company's non-GCP Phase II study in
Beijing, China evaluating NSI-566
for the treatment of chronic ischemic stroke. With this milestone
achieved, the company remains on schedule to release top line data
for the study during the fourth quarter of 2020.
About Seneca Biopharma, Inc.
Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical
company developing novel treatments for diseases of high unmet
medical need. The Company is in the process of transforming the
organization through the acquisition or in-licensing of new science
and technologies, to develop with the goal of providing meaningful
therapies for patients.
About Ischemic Stroke
Ischemic stroke, the most common type of stroke, occurs as a
result of an obstruction within a blood vessel supplying blood to
the brain. Approximately 15 million people worldwide suffer stroke
each year, of which approximately 87% are ischemic strokes.
Post-stroke motor deficits include paralysis in arms and legs and
can be permanent. No interventional therapy exists for chronic
stroke and treatment is focused on rehabilitation, but only a small
fraction of survivors achieves complete functional recovery.
Cautionary Statement Regarding Forward Looking
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Seneca's
periodic reports filed with the Securities and Exchange Commission
(SEC), including its Annual Report on Form 10-K for the year ended
December 31, 2019, its Quarterly
Reports on Form 10-Q as well as and in other reports filed with the
SEC. We do not assume any obligation to update any forward-looking
SOURCE Seneca Biopharma, Inc.